If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American ...

Having asthma, Hashimoto’s thyroiditis or atopic dermatitis in addition to alopecia areata raised the odds for early-onset, severe and prolonged alopecia areata, according to a research letter ...

Intermediate group 2 innate lymphoid cells (ILC2s) appear to be able to get around cutting-edge asthma treatments by ...

Asthma represents a substantial health burden in childhood globally, with minoritised populations being disproportionately impacted.1 Recent literature has increasingly linked social determinants of ...

Medically reviewed by Qin Rao, MD Eosinophilic esophagitis (EoE) is a chronic (long-term) condition affecting the esophagus, ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

AstraZeneca's Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreate ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

The following is a summary of “Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a ...

While treatment of EoE is complicated by a number ... 1 720 777 7457 Fax: +1 720 777 7277 [email protected]. Eosinophilic esophagitis (EoE) presents with a constellation of symptoms ...

Previously approved in China for severe eosinophilic asthma in adult and adolescent individuals of ... "China’s NMPA approves GSK’s Nucala for CRSwNP treatment" was originally created and published by ...